PERTINENT FINDINGS: We determined equivalent tumor dose–depositing injected activities of 177Lu- and 225Ac-PSMA-617 and tested treatment as single agents versus in combination against different-sized lesions. This evidence concerns the gene FOLH1 and neoplasm.